A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment

Journal of the Canadian Urological Association

Volumn 3, Issue 4, 2009, Pages 281-289

  Warren, Mark ^a   Venner, Peter M ^b   North, Scott ^a   Cheng, Tina ^c   Venner, Chris ^a   Ghosh, Sunita ^a   Venner, Allison A ^d   Finch, Daygen ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Department of Oncology ^*

^c TOM BAKER CANCER CENTRE   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70450159233     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: 10.5489/cuaj.1121     Document Type: Article

References (17)

1. Canadian cancer statistics. Toronto: Canadian Cancer Society, National Cancer Institute of Canada; 2007.
2. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;CD001425.
3. Flanigan RC, Salmon SE, Blumenstein EA. Nephrectomy followed by interferon alfa-2B compared with inteferon alfa-2B alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-1659
4. Mickisch GH, Garin A, van Poppel H, et al. RS Radical nephrectomy plus interferon-alpha-based immunotherapycompared with interferon alpha alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 2001;358:966-970
5. Flanigan RC, Mickisch GH, Sylvester R. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071-1076
6. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007;57:112-125
7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124 (Pubitemid 46089672)
8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134
9. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus Interferon (IFN)-alfa as firstline treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008;26:5024. [abstract].
10. Population by year, by province and territory. Ottawa: Statistics Canada; 2008. Available: www40.statcan.gc.ca/l01/cst01/demo02a-eng.htm (accessed 2009 July 14).
11. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-2540
12. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-296
13. Rothwell PM. External validity of randomised controlled trials: "To whom do the results of this trial apply?" Lancet 2005;365:82-93.
14. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-841
15. Heng DY, Chi KN, Murray N, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell carcinoma (mRCC); 2008 Feb 14-16; San Francisco. Genitourinary Cancers Symposium: Abstract 395; 2008.
16. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281 (Pubitemid 46849157)
17. Stein MN, Flaherty KT. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 2007;13:3765-3770